OUR portfolio

Our investments accelerate growth and stimulate private sector innovation and investment.

Filter by:
  • Achaogen

    Antibacterial drug development

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Achaogen

    Antibacterial drug development

    Achaogen focuses on the R&D and commercialization of antibacterials to combat multi-drug-resistant, Gram-negative infections. The foundation’s investment supports the development of Achaogen’s monoclonal antibody (mAb) discovery platform.
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2017
    Headquarters
    USA
  • Adjuvant Capital

    Global health–focused investment fund

    Focus areas
    Life Sciences
    Investment type
    Fund
    Status
    Active
    Adjuvant Capital

    Global health–focused investment fund

    Adjuvant, a private investment fund focused on late-stage life sciences investments to address global health challenges—including infectious diseases, sexual and reproductive health, and nutrition—received the foundation’s anchor LP support as part of the foundation’s commitment to the Global Health investment model.
    Website
    Focus areas
    Life Sciences
    Investment type
    Fund
    Status
    Active
    Initial investment
    Fund
    Partnered in
    2019
    Headquarters
    USA
    Portfolio news
    Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health
  • Affinivax

    Next-generation pneumococcal vaccine development

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Affinivax

    Next-generation pneumococcal vaccine development

    Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing multiple antigens to be incorporated in a single vaccine.
    Website
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Series A
    Partnered in
    2014
    Headquarters
    USA
    Portfolio news
    In 2022, Affinivax was acquired by GSK
  • Alere

    Point-of-care molecular diagnostics

    Focus areas
    Life Sciences
    Investment type
    Debt
    Status
    Exit
    Alere

    Point-of-care molecular diagnostics

    Expand manufacturing capabilities of point-of-care molecular testing for HIV and tuberculosis.
    Website
    Focus areas
    Life Sciences
    Investment type
    Debt
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2013
    Headquarters
    USA

  • Low-cost tech for anti-malaria treatments

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Active

    Low-cost tech for anti-malaria treatments

    Amyris develops new, low-cost technologies for manufacturing compounds to make semi-synthetic artemisinin, which can be used in anti-malaria treatments.
    Website
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Active
    Initial investment
    Public
    Partnered in
    2016
    Headquarters
    USA
  • Anacor Pharmaceuticals

    Novel small-molecule therapeutics development leverages boron chemistry

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Anacor Pharmaceuticals

    Novel small-molecule therapeutics development leverages boron chemistry

    Anacor Pharmaceuticals developed and commercialized novel therapeutics with its boron chemistry platform. The foundation’s investment helps support the development of preclinical drug candidates.
    Website
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2013
    Headquarters
    USA
    Portfolio news
    In 2016, Anacor was acquired by Pfizer
  • Arsanis

    Novel antibodies for leading cause of neonatal sepsis

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Arsanis

    Novel antibodies for leading cause of neonatal sepsis

    Arsanis focuses on the discovery and development of novel monoclonal antibodies (mAbs) to prevent and treat infectious disease. The foundation is working with Arsanis to develop a prophylactic mAb candidate targeting Stap aureus, a leading cause of neonatal sepsis that leads to around 345,000 annual deaths globally.
    Website
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Series D
    Partnered in
    2017
    Headquarters
    USA
  • Atreca

    Discovery platform for therapeutics development

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Active
    Atreca

    Discovery platform for therapeutics development

    Atreca’s proprietary discovery platform generates and develops therapeutics based on rapid characterization of human adaptive immune response at the single cell level. Foundation partners use the platform to isolate novel human monoclonal antibodies, gain immune response and vaccination insights, and generate new tools for global health vaccine discovery and development.
    Website
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Active
    Initial investment
    Series A
    Partnered in
    2012
    Headquarters
    USA
    Portfolio news
    Nasdaq: Solid tumor biotech Atreca files for a $100 million IPO
  • Beijing Bio-Institute Biological Products

    Biological product research and development

    Focus areas
    Life Sciences
    Investment type
    Debt
    Status
    Exit
    Beijing Bio-Institute Biological Products

    Biological product research and development

    Beijing Bio-Institute Biological Products researches, develops, produces, and supplies biological products.
    Focus areas
    Life Sciences
    Investment type
    Debt
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2013
    Headquarters
    China
  • BioNTech

    Cutting-edge tech for cancer, HIV, TB therapeutics

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Active
    BioNTech

    Cutting-edge tech for cancer, HIV, TB therapeutics

    BioNTech focuses on combining groundbreaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and other serious diseases. The foundation works with BioNTech on developing preclinical vaccines and immunotherapy candidates to prevent HIV and TB infection, working toward durable antiretroviral therapy-free remission of HIV disease.
    Website
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Active
    Initial investment
    Series C
    Partnered in
    2019
    Headquarters
    Germany